NorthWest Biotherapeutics Inc (NWBO)

[ae kusterer]

You asked for thoughts. To recap our conversation, I can think of several possible announcements that have some basis in fact. xxx has been to The Hill. What if they announce government funding for a trial with BMY/MRK checkpoint inhibitors that involves both the Direct and the Lysate procedures? xxx has said there are several possible funding sources. One might be the government. With Woodford still on board, why not announce what must be positive investigation results? He has been raising cash "to take advantage of severely depressed situations". To your point, why wouldn't he buy more stock with good trial and/or investigation news? Those who own the $3 options should also want to exercise with their $17 M if the stock rises. The EU/UK price negotiations have been going on long enough for resolution. The same goes for the P3 hold on "L" trial screening. Maybe there will finally be clarification of these items. It is overdue, because the P3 trial is officially scheduled to end in September. Maybe a combined EU/UK/FDA approval is partly cause for the delay? The company has had time to expand the Tennessee facility, but may be going slow for financial reasons, although a crowded Cognate parking lot has been reported by a Memphis resident on the Yahoo message board. xxx continues to stress that DCVax has the advantage of being a broad spectrum immune system activator. The application of this in the treatment of the many types of highly diverse solid tumors seems logical. It is becoming apparent that DCVax treatment of certain cancer subtypes will need checkpoint inhibitors to be effective, and a patent application has been made and accepted. Lately, the association of macrophages and PD-L1 has been recognized. NWBO and UCLA seem to be getting there technically, and it is time for Wall Street recognize the growing potential, especially the huge upside of the BMY/MRK partnerships. Lots of maybes here, but after all, Prins did say that the combination therapy caused the cancer to "disappear", at least in mice. Maybe the combination trial will delay commercialization of "L"? Maybe a special mesenchymal approval will be granted? Maybe we will hear something this week?

Sent from my iPhone